Health Tidings Mergers & AcquisitionsIncyte, Genmab Partner on KRAS G12D Colorectal Cancer Trial Incyte, Genmab Partner on KRAS G12D Colorectal Cancer Trial Read Post »
Health Tidings Mergers & AcquisitionsZymeworks Grants Roche Global Rights to ZW209 in $813M Deal Zymeworks Grants Roche Global Rights to ZW209 in $813M Deal Read Post »
Health Tidings Regulatory & Health PolicyEMA and AMA Recommend Faster Route to Bundibugyo Vaccine Trials EMA and AMA Recommend Faster Route to Bundibugyo Vaccine Trials Read Post »
Health Tidings Mergers & AcquisitionsMenarini Bets on Georgiamune’s GIM-621 With $1.1B Deal Menarini Bets on Georgiamune’s GIM-621 With $1.1B Deal Read Post »
Health Tidings Mergers & AcquisitionsAstraZeneca, Oracle Link Real-World Data With Clinical Research AstraZeneca, Oracle Link Real-World Data With Clinical Research Read Post »
Health Tidings Mergers & AcquisitionsHansoh Expands Roche ADC Deal With $15B+ in Potential Milestones Hansoh Expands Roche ADC Deal With $15B+ in Potential Milestones Read Post »
Regulatory & Health PolicyFDA Launches Cross-Center Framework to Standardize Rare Disease Drug Review FDA Launches Cross-Center Framework to Standardize Rare Disease Drug Review Read Post »
Health Tidings Mergers & AcquisitionsAdlai Nortye Partners with Eli Lilly and Merck KGaA for Phase I ADC Combina... Adlai Nortye Partners with Eli Lilly and Merck KGaA for Phase I ADC Combina... Read Post »
Health Tidings Mergers & AcquisitionsEton Secures U.S. Rights to LIBERVANT Seizure Rescue Film Eton Secures U.S. Rights to LIBERVANT Seizure Rescue Film Read Post »
Health Tidings Mergers & AcquisitionsGenerate Signs $1.2B Milestone Deal with Zealand for AI-Designed Protein Dr... Generate Signs $1.2B Milestone Deal with Zealand for AI-Designed Protein Dr... Read Post »
Health Tidings Mergers & AcquisitionsPrelude and Lilly Partner to Test PRT13722 Combinations in HR+/HER2− Brea... Prelude and Lilly Partner to Test PRT13722 Combinations in HR+/HER2− Brea... Read Post »
Health Tidings Mergers & AcquisitionsRoche and Rona Sign $1.16B Deal for ALK7-Targeting RNAi Obesity Candidate Roche and Rona Sign $1.16B Deal for ALK7-Targeting RNAi Obesity Candidate Read Post »
Health Tidings Mergers & AcquisitionsViatris to Acquire Pacira for $1.65 Billion Viatris to Acquire Pacira for $1.65 Billion Read Post »
Health Tidings Mergers & AcquisitionsShionogi Plans $2 Billion Acquisition of IntraBio to Expand Rare Disease Po... Shionogi Plans $2 Billion Acquisition of IntraBio to Expand Rare Disease Po... Read Post »
Health Tidings Mergers & AcquisitionsAlector Signs $1.27 Billion Genentech Deal for Parkinson’s Disease Therap... Alector Signs $1.27 Billion Genentech Deal for Parkinson’s Disease Therap... Read Post »
Health Tidings Mergers & AcquisitionsCSL and Alentis Partner to Advance Lixudebart in Kidney and Liver Diseases CSL and Alentis Partner to Advance Lixudebart in Kidney and Liver Diseases Read Post »
Mergers & AcquisitionsSernova and Seraxis Close $11.2 Million Financing to Advance BetaNova’s T... Sernova and Seraxis Close $11.2 Million Financing to Advance BetaNova’s T... Read Post »
Health Tidings Mergers & AcquisitionsAbogen and Novartis Partner to Advance mRNA-Encoded T-Cell Engager ABO2203 Abogen and Novartis Partner to Advance mRNA-Encoded T-Cell Engager ABO2203 Read Post »
Health Tidings Mergers & AcquisitionsItalfarmaco, JCR Sign JR-141 Licensing Deal for Hunter Syndrome Italfarmaco, JCR Sign JR-141 Licensing Deal for Hunter Syndrome Read Post »
Health Tidings Mergers & AcquisitionsRegeneron and Sanofi Expand Immunology Deal to $8B With Four Long-Acting An... Regeneron and Sanofi Expand Immunology Deal to $8B With Four Long-Acting An... Read Post »
Health Tidings Mergers & AcquisitionsAstraZeneca Invests $2 Billion in Summit to Advance Ivonescimab-ADC Combina... AstraZeneca Invests $2 Billion in Summit to Advance Ivonescimab-ADC Combina... Read Post »
Health Tidings Mergers & AcquisitionsNovo Secures Global Rights to Hengrui’s Once-Weekly Oral GLP-1/GIP Agonis... Novo Secures Global Rights to Hengrui’s Once-Weekly Oral GLP-1/GIP Agonis... Read Post »
Health Tidings Mergers & AcquisitionsMerck and SciBrunch Sign $2.13 Billion Deal for KRAS G12D Inhibitor SPR2015 Merck and SciBrunch Sign $2.13 Billion Deal for KRAS G12D Inhibitor SPR2015 Read Post »
Health Tidings Mergers & AcquisitionsHenlius, Amberstone Develop Tumor-Activated TCEs for Solid Tumors Henlius, Amberstone Develop Tumor-Activated TCEs for Solid Tumors Read Post »
Health Tidings Mergers & AcquisitionsAtavistik Bio, Roche Partner on Allosteric CVRM Drugs Atavistik Bio, Roche Partner on Allosteric CVRM Drugs Read Post »
Health Tidings Mergers & AcquisitionsLexeo Expands Friedreich Ataxia Pipeline With Mantle Acquisition Lexeo Expands Friedreich Ataxia Pipeline With Mantle Acquisition Read Post »
Health Tidings Mergers & AcquisitionsEnvisagenics, Boehringer Partner on RNA Splicing Cancer Targets Envisagenics, Boehringer Partner on RNA Splicing Cancer Targets Read Post »
Health Tidings Mergers & AcquisitionsAbbVie and Iambic Partner to Accelerate AI-Driven Small-Molecule Drug Disco... AbbVie and Iambic Partner to Accelerate AI-Driven Small-Molecule Drug Disco... Read Post »
Health Tidings Mergers & AcquisitionsTelix to Acquire ITM in $1.65 Billion Radiopharmaceutical Deal Telix to Acquire ITM in $1.65 Billion Radiopharmaceutical Deal Read Post »
Mergers & Acquisitions1ST-104 Parkinson’s Drug Licensed by SK Biopharmaceuticals 1ST-104 Parkinson’s Drug Licensed by SK Biopharmaceuticals Read Post »
Health Tidings Mergers & AcquisitionsRoche, Dualitas Launch Bispecific Antibody Discovery Deal Roche, Dualitas Launch Bispecific Antibody Discovery Deal Read Post »
Health Tidings Mergers & AcquisitionsLisata Acquires Marea, Raises $225M for Cardioendocrine Drug Development Lisata Acquires Marea, Raises $225M for Cardioendocrine Drug Development Read Post »
Health Tidings Mergers & AcquisitionsNovo Nordisk and Anthropic Partner to Accelerate AI-Driven Drug Discovery Novo Nordisk and Anthropic Partner to Accelerate AI-Driven Drug Discovery Read Post »
Health Tidings Mergers & AcquisitionsGSK to Acquire Chimagen’s Trispecific T-Cell Engager for Multiple Myeloma GSK to Acquire Chimagen’s Trispecific T-Cell Engager for Multiple Myeloma Read Post »
Health Tidings Mergers & AcquisitionsHUTCHMED Licenses KRAS-EGFR Therapy to GSK in $1.3 Billion Deal HUTCHMED Licenses KRAS-EGFR Therapy to GSK in $1.3 Billion Deal Read Post »
Health Tidings Mergers & AcquisitionsDualityBio, Genentech Strike ADC Deal Worth More Than $1 Billion in Potenti... DualityBio, Genentech Strike ADC Deal Worth More Than $1 Billion in Potenti... Read Post »
Health Tidings Mergers & AcquisitionsMcKesson to Acquire Precision Medicine Group for $2.25 Billion, Expanding C... McKesson to Acquire Precision Medicine Group for $2.25 Billion, Expanding C... Read Post »
Health Tidings Mergers & AcquisitionsHanmi Pharm Signs Up to $2.3 Billion Genentech Deal for Obesity Candidate H... Hanmi Pharm Signs Up to $2.3 Billion Genentech Deal for Obesity Candidate H... Read Post »
Health Tidings Mergers & AcquisitionsWerewolf Therapeutics and Ambros Therapeutics Merge to Advance Neridronate ... Werewolf Therapeutics and Ambros Therapeutics Merge to Advance Neridronate ... Read Post »
Health Tidings Mergers & AcquisitionsChai Discovery and Bristol Myers Squibb Partner to Advance AI-Driven Antibo... Chai Discovery and Bristol Myers Squibb Partner to Advance AI-Driven Antibo... Read Post »
Health Tidings Mergers & AcquisitionsTolerance Bio Advances Efineptakin Alfa into Phase 2 Development for Thymic... Tolerance Bio Advances Efineptakin Alfa into Phase 2 Development for Thymic... Read Post »
Health Tidings Mergers & AcquisitionsFulcrum-Slate Merger Creates New Platform to Advance Next-Generation Migrai... Fulcrum-Slate Merger Creates New Platform to Advance Next-Generation Migrai... Read Post »
Health Tidings Mergers & AcquisitionsIDEAYA and Genentech Partner to Evaluate IDE892 Plus GDC-7035 in PDAC IDEAYA and Genentech Partner to Evaluate IDE892 Plus GDC-7035 in PDAC Read Post »
Health Tidings Mergers & AcquisitionsChugai’s AID351 Anti-Dengue Antibody Licensed to GSK for Clinical Develop... Chugai’s AID351 Anti-Dengue Antibody Licensed to GSK for Clinical Develop... Read Post »
Health Tidings Mergers & AcquisitionsBioMarin to Acquire Alesta Therapeutics for $275 Million Upfront to Advance... BioMarin to Acquire Alesta Therapeutics for $275 Million Upfront to Advance... Read Post »
Health Tidings Mergers & AcquisitionsLEO Pharma Agrees to Acquire Dersimelagon, Expanding Late-Stage Rare Dermat... LEO Pharma Agrees to Acquire Dersimelagon, Expanding Late-Stage Rare Dermat... Read Post »
Mergers & AcquisitionsOmniAb and Lilly Launch New Ion Channel Discovery Collaboration Worth Up to... OmniAb and Lilly Launch New Ion Channel Discovery Collaboration Worth Up to... Read Post »
Mergers & AcquisitionsZealand Pharma Sells Rusfertide Royalty Rights to Royalty Pharma for $100 M... Zealand Pharma Sells Rusfertide Royalty Rights to Royalty Pharma for $100 M... Read Post »
Health Tidings Mergers & AcquisitionsSentynl Secures U.S. Option for Mereo’s Alvelestat Ahead of Phase 3 in AA... Sentynl Secures U.S. Option for Mereo’s Alvelestat Ahead of Phase 3 in AA... Read Post »
Mergers & AcquisitionsJazz Pharmaceuticals to Acquire Actio Biosciences to Expand Rare Epilepsy P... Jazz Pharmaceuticals to Acquire Actio Biosciences to Expand Rare Epilepsy P... Read Post »
